InflaRx Closes $150 Million Underwritten Public Offering, Confirming Significant Dilution
Summary
InflaRx N.V. announced the closing of its previously disclosed $150 million underwritten public offering, selling 75 million ordinary shares at $2.00 per share, which significantly dilutes existing shareholders.
Key Events
-
Offering Closed
InflaRx N.V. completed its underwritten public offering on May 7, 2026.
-
Proceeds and Shares
The company raised approximately $150 million by selling 75 million ordinary shares.
-
Pricing at Discount
Shares were sold at $2.00 each, a notable discount to the current market price of $2.6602.
-
Significant Dilution
The offering represents a substantial increase in outstanding shares, leading to significant dilution for current shareholders.
Analysis
This 6-K confirms the completion of the substantial capital raise that was initiated with the 424B5 filing yesterday. The offering of 75 million shares for $150 million represents a significant dilution for existing shareholders, especially given the offering price of $2.00 per share was at a notable discount to the current market price of $2.6602. While the capital infusion provides liquidity into 2027, as mentioned in recent Q1 results, the terms of the offering indicate a high cost of capital and will likely exert downward pressure on the stock. Investors should monitor the company's use of these proceeds and future capital needs.
At the time of this filing, IFRX was trading at $2.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.6M. The 52-week trading range was $0.71 to $2.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.